Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin for Primary Prophylaxis of Clostridioides Difficile Infection
NCT07221708Phase 3Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2027
- Primary completion
- Dec 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by University of Maryland, Baltimore. Planned start Jan 2027; status: withdrawn.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07221708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221708.